【摘要】 目的综述ALK/ROS1抑制剂治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的最新研究进展。方法通过查阅文献,对治疗晚期NSCLC患者的ALK/ROS1抑制剂进行总结。结果克唑替尼被报道在NSCLC病人中抑制间变性淋巴瘤激酶(ALK)和ROS1重排高度有效和耐受性良好,但在初始治疗后的9~12个月出现了耐药问题,随后又有一些新的ALK抑制剂被研发出来。结论耐药基因的发现及新ALK/ROS1抑制剂的研发具有重要意义和广阔前景。更多还原

【Abstract】 Objective Toreview the latest research progress of ALK/ROS1 inhibitors in the treatment of advanced non-small cell lung cancer( NSCLC). Methods By review ing the literature,w e summarize the ALK/ROS1 inhibitors in the treatment of advanced NSCLC. Results Crizotinib w as reported to be highly effective and w ell tolerated in inhibiting the alteration of anaplastic lymphoma kinase( ALK) and ROS1 in NSCLC patients,How ever,resistance to crizotinib emerges after treatment for 9 to 12 months,follow ed by several new ALK inhibitors have been developed. Conclusion The discovery of drug-resistant genes and the development of new ALK/ROS1 inhibitors have great significance and broad prospects.更多还原